JP2012519681A5 - - Google Patents

Download PDF

Info

Publication number
JP2012519681A5
JP2012519681A5 JP2011552537A JP2011552537A JP2012519681A5 JP 2012519681 A5 JP2012519681 A5 JP 2012519681A5 JP 2011552537 A JP2011552537 A JP 2011552537A JP 2011552537 A JP2011552537 A JP 2011552537A JP 2012519681 A5 JP2012519681 A5 JP 2012519681A5
Authority
JP
Japan
Prior art keywords
leukocytes
composition
cells
wound
ulcer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011552537A
Other languages
English (en)
Japanese (ja)
Other versions
JP5713924B2 (ja
JP2012519681A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2010/000882 external-priority patent/WO2010100570A2/en
Publication of JP2012519681A publication Critical patent/JP2012519681A/ja
Publication of JP2012519681A5 publication Critical patent/JP2012519681A5/ja
Application granted granted Critical
Publication of JP5713924B2 publication Critical patent/JP5713924B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011552537A 2009-03-05 2010-03-05 活性化白血球組成物 Expired - Fee Related JP5713924B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20929809P 2009-03-05 2009-03-05
US61/209,298 2009-03-05
US21158709P 2009-04-01 2009-04-01
US61/211,587 2009-04-01
PCT/IB2010/000882 WO2010100570A2 (en) 2009-03-05 2010-03-05 Activated leukocyte composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015046833A Division JP2015129180A (ja) 2009-03-05 2015-03-10 活性化白血球組成物

Publications (3)

Publication Number Publication Date
JP2012519681A JP2012519681A (ja) 2012-08-30
JP2012519681A5 true JP2012519681A5 (https=) 2013-03-28
JP5713924B2 JP5713924B2 (ja) 2015-05-07

Family

ID=42710060

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011552537A Expired - Fee Related JP5713924B2 (ja) 2009-03-05 2010-03-05 活性化白血球組成物
JP2015046833A Pending JP2015129180A (ja) 2009-03-05 2015-03-10 活性化白血球組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015046833A Pending JP2015129180A (ja) 2009-03-05 2015-03-10 活性化白血球組成物

Country Status (15)

Country Link
EP (2) EP2403509B1 (https=)
JP (2) JP5713924B2 (https=)
KR (1) KR101548783B1 (https=)
CN (1) CN102438635B (https=)
AU (1) AU2010220132B2 (https=)
BR (1) BRPI1006759A2 (https=)
CA (2) CA2867976A1 (https=)
DK (1) DK2403509T3 (https=)
ES (1) ES2428102T3 (https=)
IL (1) IL214953A0 (https=)
MX (1) MX2011009277A (https=)
PL (1) PL2403509T3 (https=)
RU (2) RU2015102067A (https=)
WO (1) WO2010100570A2 (https=)
ZA (1) ZA201107269B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8574902B2 (en) 2009-03-05 2013-11-05 Macrocure Ltd. Activated leukocyte composition and uses for wound healing
JP2013537889A (ja) 2010-09-09 2013-10-07 マクロキュア，リミテッド 活性化白血球馴化上清および創傷治癒のための使用
EP2825182A1 (en) 2012-03-15 2015-01-21 Macrocure, Ltd. Activated immunostimulatory cell composition for therapy of infection
US20150030635A1 (en) 2012-03-15 2015-01-29 Macrocure, Ltd. Activated Immunostimulatory Cell Composition and Uses Thereof
EP2781224A1 (en) 2013-03-18 2014-09-24 Khorionyx Implantable preparations comrpsing globin insoluble at physiological pH and serum for regeneration of tissues and treatment of wounds.
EP3258945B1 (en) 2015-02-16 2020-10-07 Nayacure Therapeutics Ltd. Modified blood clots
GB201618106D0 (en) 2016-10-26 2016-12-07 Lift Biosciences Ltd Cancer-killing cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60120821A (ja) * 1983-12-05 1985-06-28 Asahi Chem Ind Co Ltd 悪性腫瘍治療用白血球刺激材および刺激方法
US4751001A (en) * 1984-09-24 1988-06-14 Becton Dickinson And Company Blood partitioning apparatus
JPH02167071A (ja) * 1988-12-19 1990-06-27 Terumo Corp 非ヒト動物由来白血球系細胞の分離材、分離器および分離方法
JPH07102151B2 (ja) * 1994-06-03 1995-11-08 中外製薬株式会社 新規なポリペプチドの製造法
US6146890A (en) 1994-07-03 2000-11-14 Danon; David Method and system for cultivating macrophages
IL110195A (en) * 1994-07-03 2003-10-31 David Danon Method and system for cultivating macrophages
JP3201610B2 (ja) * 1995-03-17 2001-08-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 腫瘍を処置する方法
JPH10259134A (ja) * 1997-01-16 1998-09-29 Sekisui Chem Co Ltd 創傷治癒促進剤
RU2143685C1 (ru) * 1998-05-19 1999-12-27 Коган Александр Харитонович Способ дифференциального подсчета гранулоцитов, моноцитов и лимфоцитов
CN1335757A (zh) * 1998-11-12 2002-02-13 聚合体生物科学公司 可用于快速凝血和止血的止血聚合物
MXPA04004813A (es) * 2001-11-21 2004-08-11 Yeda Res & Dev Procedimientos para la produccion de leucocitos fagociticos mononucleares humanos.
JP4108393B2 (ja) * 2002-07-15 2008-06-25 テルモ株式会社 細胞増殖剤の製造方法
JP4245324B2 (ja) * 2002-10-09 2009-03-25 旭化成クラレメディカル株式会社 単球の分離回収方法
EP2198873A1 (en) * 2008-12-18 2010-06-23 Aposcience AG Pharmaceutical preparation comprising supernatant of blood mononuclear cell culture
EP2201954A1 (en) * 2008-12-18 2010-06-30 Aposcience AG Pharmaceutical preparation

Similar Documents

Publication Publication Date Title
JP2012519681A5 (https=)
RU2707254C1 (ru) Водный фармацевтический препарат и способ лечения хронической язвы
GB2462228A (en) Providing hemostasis in anticoagulated blood by using zeolites
JP2013541010A5 (https=)
Jain et al. Anti-inflammatory effects of Erythromycin and Tetracycline on Propionibacterium. acnes induced production of chemotactic factors and reactive oxygen species by human neutrophils
RU2017121191A (ru) Методика размножения гамма-дельта Т-клеток
RU2011139016A (ru) Активированная лейкоцитарная композиция
EP2895209B1 (en) Improved wound healing compositions comprising microspheres
JP2013528230A (ja) ノーオプション重症虚血肢（ｃｌｉ）を処置するための組成物および方法
Roquilly et al. Toll-like receptor-4 agonist in post-haemorrhage pneumonia: role of dendritic and natural killer cells
JP2013507945A5 (https=)
Uke et al. The ideal donor site dressing: a comparison of a chitosan-based gelling dressing to traditional dressings
WO2017060821A1 (en) Hemostatic composition
Tsang et al. The use of recombinant human epidermal growth factor (rhEGF) in a gentleman with drug-induced Steven Johnson syndrome
Gormley et al. The effect of methylprednisolone on cytokine concentration and leukocyte adhesion molecule expression in an isolated cardiopulmonary bypass system
WO2018156052A1 (en) Antiseptic composition comprising unithiol and dimethylsulfoxide, use of the composition and method of wound treatment with its use
Stone et al. The effect of arsenic on inflammation
BR102013031043A2 (pt) Uso de compostos químicos capazes de inibir a ação tóxica das esfingomielinases d do veneno de aranhas loxosceles e composição farmacêutica compreendendo os referidos compostos
JP2015140334A (ja) 組織修復性マクロファージへの分化誘導剤および組織修復性マクロファージの製造方法
Martires et al. Graft-versus-host disease
NO Cadexomer iodine ointment vs povidine Iodine ointment in diabetic ulcer Dressing-a randomised control trial at a Teritiary care center
Singh et al. Comparative evaluation of haemato-biochemical changes during infected wound healing in cow calves with the use of silver nano particle gel and povidone iodine
Sippenauer et al. 3036–BONE MARROW TRANSPLANTATION COMPROMISES THE REGENERATIVE CAPACITY OF THE BONE MARROW NICHE
Dufour-Gaume et al. Early and repeated use of plasma for the management of Ebola patients: reflection around a case
Patil NEGATIVE PRESSURE WOUND THERAPY VERSUS CONVENTIONAL DRESSING IN TREATMENT OF INFECTED CHRONIC WOUNDS IN RURAL HOSPITAL: A PROSPECTIVE CASE CONTROL STUDY.